Date:5/1/2012

linical research customers; (9) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (10) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (11) our ability to defend our existing intellectual property and obtain protection for intellectual property we develop in the future; (12) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; (13) our dependence on third-party vendors; and (14) the ability of new members of our senior management to make a successful transition into their new roles and for all members of senior management to ultimately develop and implement a strategic plan.  These and other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2011.Contact:

Gregg O. Lehman, Ph.D.

Joe Dorame, Robert Blum, Joe DiazAngeion Corporation

Lytham Partners, LLCChief Executive Officer and President

(602) 889-9700(651) 484-4874

angn@lythampartners.com
'/>"/>

SOURCE Angeion Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Angeion Selects Hendrik Struik for Board of Directors
2. Wendy D. Lynch, Ph.D., Joins Angeions Board of Directors
3. Angeion Corporation Reports First Quarter Fiscal Year 2012 Operating Results
4. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
5. Angeion Corporation Reports Fourth Quarter and Fiscal Year 2011 Operating Results
6. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
7. Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results
8. Angeion Corporation to Report Third Quarter Fiscal Year 2011 Financial Results on Thursday, September 1, 2011
9. GenWay Biotech Appoints New Vice President of Custom/OEM
10. Elsevier Appoints New President of Elsevier CPM Resource Center
11. Nephros Appoints John C. Houghton as President and Chief Executive Officer